In vitro activity of daptomycin against Staphylococci isolated from bacteremia and community-onset skin and soft tissue infections in France: Data from two nationwide studies

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 28, Issue 10, 2009, Pages 1209-1215

  Gallon, O ^a   Guillet Caruba, C ^b   Lamy, B ^c   Laurent, F ^d,e   Doucet Populaire, F ^b,f   Decousser, J W ^b  

^a Centre Hospitalier de Dourdan   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c Centre Hospitalier du Bassin de Thau   (France)

^d INSERM   (France)

^e CROIX ROUSSE HOSPITAL   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; LINEZOLID; OXACILLIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTEREMIA; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; FRANCE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; COAGULASE; COLONY COUNT, MICROBIAL; COMMUNITY-ACQUIRED INFECTIONS; DAPTOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; FRANCE; HUMANS; MICROBIAL SENSITIVITY TESTS; OXACILLIN; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS; TREATMENT OUTCOME;

EID: 70349690493     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10096-009-0764-y     Document Type: Article

References (34)

1. GJ Moet RN Jones DJ Biedenbach, et al. 2007 Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004) Diagn Microbiol Infect Dis 57 7 13 10.1016/j.diagmicrobio.2006.05.009 17059876 10.1016/j.diagmicrobio.2006.05.009 (Pubitemid 44908825)
2. JW Decousser P Pina F Picot, et al. 2003 Frequency of isolation and antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections: a French prospective national survey J Antimicrob Chemother 51 1213 1222 10.1093/jac/dkg201 12697655 10.1093/jac/dkg201 1:CAS:528:DC%2BD3sXjsVKlsLs%3D (Pubitemid 36622077)
3. JW Decousser P Pina F Viguier, et al. 2004 Invasive Streptococcus pneumoniae in France: antimicrobial resistance, serotype, and molecular epidemiology findings from a monthly national study in 2000 to 2002 Antimicrob Agents Chemother 48 3636 3639 10.1128/AAC.48.9.3636-3639.2004 15328146 10.1128/AAC.48.9.3636-3639.2004 1:CAS:528:DC%2BD2cXnsVeht7w%3D (Pubitemid 39129380)
4. M Galas JW Decousser N Breton, et al. 2008 Nationwide study of the prevalence, characteristics, and molecular epidemiology of extended-spectrum- β-lactamase-producing Enterobacteriaceae in France Antimicrob Agents Chemother 52 786 789 10.1128/AAC.00906-07 18025119 10.1128/AAC.00906-07 1:CAS:528:DC%2BD1cXhtlWjsb8%3D (Pubitemid 351170867)
5. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Clinical breakpoints. Available online at: http://www.srga.org/eucastwt/MICTAB/ index.html
6. French Society of Microbiology (CASFM) Guidelines of the Antimicrobial Committee of the French Society of Microbiology. Available online at: http://www.sfm.asso.fr/nouv/general.php?pa=2
7. G Lina Y Piémont F Godail-Gamot, et al. 1999 Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia Clin Infect Dis 29 1128 1132 10.1086/313461 10524952 10.1086/313461 1:STN:280:DyaK1MvlsVKntA%3D%3D (Pubitemid 30265628)
8. MH Kollef 2007 Limitations of vancomycin in the management of resistant staphylococcal infections Clin Infect Dis 45 Suppl 3 S191 S195 10.1086/519470 17712746 10.1086/519470 1:CAS:528:DC%2BD2sXhtFahtrrN (Pubitemid 47378906)
9. TP Lodise J Graves A Evans, et al. 2008 Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin Antimicrob Agents Chemother 52 3315 3320 10.1128/AAC.00113-08 18591266 10.1128/AAC.00113-08 1:CAS:528:DC%2BD1cXhtF2gt77I
10. TP Lodise B Lomaestro J Graves GL Drusano, et al. 2008 Larger vancomycin doses Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin Antimicrob Agents Chemother 52 1330 1336 18227177 10.1128/AAC.01602-07 1:CAS:528:DC%2BD1cXksFajtro%3D
11. European Antimicrobial Resistance Surveillance System (EARSS) Home page at: http://www.rivm.nl/earss
12. F Vandenesch T Naimi MC Enright, et al. 2003 Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence Emerg Infect Dis 9 978 984 12967497
13. RS Daum 2007 Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus N Engl J Med 357 380 390 10.1056/NEJMcp070747 17652653 10.1056/NEJMcp070747 1:CAS:528: DC%2BD2sXotFCqs7w%3D (Pubitemid 47124138)
14. JH Jorgensen SA Crawford 2006 Assessment of two commercial susceptibility test methods for determination of daptomycin MICs J Clin Microbiol 44 2126 2129 10.1128/JCM.00076-06 16757608 10.1128/JCM.00076-06 1:CAS:528: DC%2BD28XmvFKgsbw%3D (Pubitemid 43902163)
15. LA Jevitt GM Thorne MM Traczewski, et al. 2006 Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates J Clin Microbiol 44 3098 3104 10.1128/JCM.00665-06 16954233 10.1128/JCM.00665-06 1:CAS:528:DC%2BD28XhtVGnt7%2FJ (Pubitemid 44413737)
16. JM Streit RN Jones HS Sader 2004 Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms J Antimicrob Chemother 53 669 674 10.1093/jac/dkh143 14985278 10.1093/jac/dkh143 1:CAS:528: DC%2BD2cXisF2lsrk%3D (Pubitemid 38499788)
17. HS Sader JM Streit TR Fritsche, et al. 2006 Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004) Clin Microbiol Infect 12 844 852 10.1111/j.1469-0691.2006.01550.x 16882289 10.1111/j.1469-0691.2006.01550.x 1:CAS:528:DC%2BD28XhtVeht7bL (Pubitemid 44151284)
18. HS Sader AA Watters TR Fritsche, et al. 2007 Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005) BMC Infect Dis 7 29 10.1186/1471-2334-7-29 17442104 10.1186/1471-2334-7-29 (Pubitemid 46745435)
19. IA Critchley DC Draghi DF Sahm, et al. 2003 Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001 J Antimicrob Chemother 51 639 649 10.1093/jac/dkg130 12615866 10.1093/jac/dkg130 1:CAS:528:DC%2BD3sXit12ltL4%3D (Pubitemid 36336158)
20. SN Leonard CM Cheung MJ Rybak 2008 Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 52 2974 2976 10.1128/AAC.00257-08 18519721 10.1128/AAC.00257-08 1:CAS:528: DC%2BD1cXps1Ogu78%3D
21. AC Fluit FJ Schmitz J Verhoef, et al. 2004 In vitro activity of daptomycin against Gram-positive European clinical isolates with defined resistance determinants Antimicrob Agents Chemother 48 1007 1011 10.1128/AAC.48.3.1007-1011.2004 14982796 10.1128/AAC.48.3.1007-1011.2004 1:CAS:528:DC%2BD2cXitVGhtLc%3D (Pubitemid 38280356)
22. GJ Moran A Krishnadasan RJ Gorwitz, et al. 2006 Methicillin-resistant S. aureus infections among patients in the emergency department N Engl J Med 355 666 674 10.1056/NEJMoa055356 16914702 10.1056/NEJMoa055356 1:CAS:528: DC%2BD28Xot12mtLo%3D (Pubitemid 44244537)
23. ML Grayson 2007 The treatment triangle for staphylococcal infections N Engl J Med 355 724 727 10.1056/NEJMe068152 10.1056/NEJMe068152
24. FC Tenover RC Moellering 2007 The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus Clin Infect Dis 44 1208 1215 10.1086/513203 17407040 10.1086/513203 1:CAS:528:DC%2BD2sXlsVyiur0%3D (Pubitemid 46651246)
25. SE Cosgrove VG Fowler Jr 2008 Management of methicillin-resistant Staphylococcus aureus bacteremia Clin Infect Dis 46 Suppl 5 S386 S393 10.1086/533595 18462094 10.1086/533595 1:CAS:528:DC%2BD1cXnsFKqt7s%3D (Pubitemid 351717326)
26. ST Micek 2007 Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections Clin Infect Dis 45 Suppl 3 S184 S190 10.1086/519471 17712745 10.1086/519471 1:CAS:528:DC%2BD2sXhtFahtrrM (Pubitemid 47378905)
27. EH Ben Mansour E Jacob M Monchi, et al. 2003 Occurrence of MRSA endocarditis during linezolid treatment Eur J Clin Microbiol Infect Dis 22 372 373 10.1007/s10096-003-0959-6 12768433 10.1007/s10096-003-0959-6 1:STN:280:DC%2BD3s3ptFKlsg%3D%3D (Pubitemid 36836624)
28. CK Naber 2008 Future strategies for treating Staphylococcus aureus bloodstream infections Clin Microbiol Infect 14 Suppl 2 26 34 18226087 1:CAS:528:DC%2BD1cXjsl2lsLY%3D
29. HW Boucher G Sakoulas 2007 Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus Clin Infect Dis 45 601 608 10.1086/520655 17682996 10.1086/520655 1:CAS:528:DC%2BD2sXhtVOrs7fF (Pubitemid 47328642)
30. PM Small HF Chambers 1990 Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users Antimicrob Agents Chemother 34 1227 1231 2393284 1:STN:280:DyaK3czmsFCksA%3D%3D
31. RN Jones TR Fritsche HS Sader, et al. 2007 Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries Diagn Microbiol Infect Dis 59 199 209 10.1016/j.diagmicrobio.2007.06.001 17908617 10.1016/j. diagmicrobio.2007.06.001 1:CAS:528:DC%2BD2sXhtFSksLrE (Pubitemid 47484135)
32. J Weigelt K Itani D Stevens, et al. 2005 Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections Antimicrob Agents Chemother 49 2260 2266 10.1128/AAC.49.6.2260-2266.2005 15917519 10.1128/AAC.49.6.2260-2266.2005 1:CAS:528:DC%2BD2MXkvFChu7k%3D (Pubitemid 40734452)
33. DL Stevens D Herr H Lampiris, et al. 2002 Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections Clin Infect Dis 34 1481 1490 10.1086/340353 12015695 10.1086/340353 1:CAS:528:DC%2BD38XltFamtrk%3D (Pubitemid 34553708)
34. MC Birmingham CR Rayner AK Meagher, et al. 2003 Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program Clin Infect Dis 36 159 168 10.1086/345744 12522747 10.1086/345744 1:CAS:528:DC%2BD3sXht1ymsrk%3D (Pubitemid 36143412)